Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pure Extracts Technologies was a Canadian plant-based extraction and product manufacturing company focused on cannabis, hemp, functional mushrooms, and psychedelic-derived formulations. The company operated an extraction and processing facility in British Columbia and offered both white-label/toll processing services and its own product development capabilities. Its commercial products included cannabis derivatives such as vapes, gummies, and oils, while it also explored psilocybin-based formulation work in oral and nasal dosage forms. The business appeared to sit at the intersection of cannabinoid extraction, consumer packaged health products, and emerging psychedelic formulation. However, the company became financially distressed, its manufacturing subsidiary entered bankruptcy proceedings in 2023, and its common shares were delisted from the Canadian Securities Exchange in December 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pure Extracts Technologies.